Weight Loss Medications

* All indicated fields must be completed.
Please include non-medical questions and correspondence only.

Semaglutide (Wegovy) gained FDA approval for treating obesity in 2021, marking a significant milestone. Other prescription weight loss drugs, some with longer histories of use, include Liraglutide, bupropion/naltrexone (contrave), phentermine (in various doses), Phentermine-Topiramate combination (Qysmia), and numerous other GLP-1 agonists or GIP/GLP-1 agonists. Expectations are high for the unveiling of newer drugs in the future.

We offer tailored medication programs to meet individual needs, with each medication leveraging unique mechanisms to aid in weight loss. It's crucial to understand the diverse side-effect profiles associated with these medications.

GLP-1 Agonists

Among the GLP-1 Agonists are Liraglutide (Saxenda), Dulaglutide (Trulicity), Semaglutide (Wegovy), Exenatide extended release (Bydureon bcise) (weekly), and Exenatide (Byetta) (twice daily). GLP-1RAs function by curbing appetite and hunger sensations, slowing down food release from the stomach, and promoting feelings of fullness after meals.

New anti-obesity drugs are narrowing the gap between traditional dieting and medical intervention.

New anti-obesity drugs are closing gap between dieting and ...


Tirzepatide (Mounjaro) which is approved for use in T2DM can also help you lose weight with dual actions similar to GLP1 Agonists.

GLP-1 agonists and GIP/GLP-1 agonists represent a promising frontier in the realm of weight management and metabolic health. These medications target key pathways involved in appetite regulation, glucose metabolism, and energy expenditure, offering a multifaceted approach to combating obesity and related metabolic disorders.

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones produced by the gut in response to nutrient ingestion. They play crucial roles in regulating insulin secretion, glucose uptake, and satiety signaling.

By leveraging the synergistic actions of both GLP-1 and GIP, medications like Tirzepatide (Mounjaro) offer a dual-action mechanism for weight management. Tirzepatide acts as a dual agonist of the GLP-1 and GIP receptors, enhancing insulin secretion, suppressing glucagon release, and promoting feelings of fullness.

This dual-action approach addresses multiple facets of the underlying pathophysiology of obesity and insulin resistance, making it a promising therapeutic option for individuals struggling with weight loss and metabolic dysregulation.

Moreover, emerging research suggests that targeting both the GLP-1 and GIP pathways may lead to synergistic effects on body weight, glucose control, and cardiovascular health. By harnessing the combined benefits of these incretin hormones, healthcare providers can offer patients a comprehensive and personalized approach to weight management.

What are Compounded GLP-1 Medications?

Recognizing the challenges posed by the limited availability of semaglutide and other GLP-1s, we've established robust partnerships with specialized compounding pharmacies. These pharmacies possess the expertise and capabilities to create bespoke formulations of GLP-1 medications tailored specifically for off-label use in weight loss interventions.

Compound medications offer a unique avenue for addressing individual patient needs with precision and flexibility. Through compounding, we can customize dosages, adjust formulations, and even combine multiple active ingredients to optimize treatment outcomes. This approach ensures that patients receive personalized care that aligns with their unique physiological profiles, preferences, and treatment goals.

Moreover, compounded medications undergo rigorous quality control measures to uphold safety, efficacy, and consistency. Pharmacists meticulously source high-quality ingredients and adhere to stringent compounding standards to produce medications of the highest caliber.

Our collaboration with reputable compounding pharmacies underscores our commitment to innovation and patient-centered care. By harnessing the potential of compound GLP-1 medications, we empower patients with access to tailored solutions that transcend conventional treatment paradigms.

Accessibility Toolbar